Why this is on people's radar
AICAR's profile mostly traces back to one paper. In 2008, Ronald Evans and colleagues at the Salk Institute published a Cell paper showing that AICAR alone, without any exercise, increased treadmill endurance in untrained mice by about 44% over four weeks. The same study showed AICAR enhanced exercise-induced gene-expression changes when paired with training. The paper got widespread media coverage as the "exercise in a pill" finding.
The World Anti-Doping Agency banned AICAR almost immediately, partly in response to that paper and partly because of broader concern about metabolic-modulator doping. The pharmaceutical-development story has been smaller. AICAR was tested clinically in cardiac contexts (during cardiac surgery to limit ischemia-reperfusion injury) without producing decisive results that supported FDA approval. The compound has continued in research use and in research-peptide channels, but it never became a major clinical-development success.
SLU-PP-332 (covered separately) is the more recent exercise-mimetic compound that's generating similar attention to what AICAR generated in 2008. The pattern of "preclinical exercise-mimetic with a striking mouse paper that doesn't translate easily to humans" is a recurring theme in this corner of pharmacology.
What people are usually trying to do with it
People exploring AICAR are usually focused on:
- Exercise-mimetic effects, metabolic benefit without proportional gym time
- Endurance support layered on top of training
- Fat oxidation and metabolic flexibility
- Following the longevity research at the AMPK-activator end of the field
What the science actually shows
Plain-English summary:
AMPK activation (well-characterized)
AICAR is metabolized to ZMP, an AMP analog that activates AMPK directly. The biochemistry is well-established and AICAR is a routine research tool for studying AMPK biology.
Mouse endurance findings
The 2008 Evans-lab paper reported the famous ~44% endurance increase in untrained mice. Subsequent animal work has been mixed, some studies replicated the effect, others didn't, and the relevant pharmacokinetics turn out to be tricky.
Cardiac surgery trials (mixed)
AICAR (as acadesine) was tested in cardiac surgery to reduce ischemia-reperfusion injury. Results were mixed and didn't lead to FDA approval.
What hasn't been demonstrated
Approved clinical use. Robust human-translation evidence for the mouse exercise-mimetic effect at oral or subcutaneous doses practical for humans. Long-term safety with chronic use in healthy adults.
The honest read
What's solid:
The AMPK-activation mechanism is real, well-characterized, and useful as a research tool. The 2008 mouse paper is real preclinical work.
What's still unproven:
Whether the mouse-paper effects translate to humans at practical doses. Pharmacokinetic considerations (oral bioavailability, distribution to muscle) make AICAR less straightforward to translate than the original headlines implied.
What's hyped beyond the evidence:
"Exercise in a pill" framings. The mouse data is real, the human translation has been limited, and AICAR has had over 15 years to advance through clinical development without producing approved use cases. Anyone using it in research-peptide channels is participating in self-experimentation with unclear benefit.
Things to know if you're looking into it
- Not technically a peptide: small-molecule AMPK activator, included on this site because of overlapping wellness-and-fat-loss conversation.
- WADA banned: competitive athletes will test positive.
- Regulatory status: not FDA-approved. Not on the FDA Category 2 list.
- How it's used in research: typically subcutaneous or IV. Oral bioavailability is poor.
- Cumulative-exposure considerations: AMPK is a master metabolic regulator; long-term broad activation has unknown chronic effects.
- Specific dosing protocols, mechanism, and the full reference list: all in the "Want to go deeper?" section below.
What people often ask
Does AICAR really replace exercise?
The 2008 mouse data was striking; human translation has been limited. The "exercise in a pill" framing has been around for 15+ years without producing approved clinical use cases.
Is it FDA-approved?
No. Tested in cardiac surgery contexts without producing decisive results.
Will I test positive on a drug test?
Yes. AICAR is on the WADA banned list.
How does it compare to SLU-PP-332?
Different mechanisms (AICAR activates AMPK; SLU-PP-332 activates ERR receptors). Both are preclinical exercise-mimetic candidates from different research lineages.
FDA and regulatory status
Status as of May 5, 2026: Not FDA-approved. On the World Anti-Doping Agency Prohibited List. Not on the FDA Category 2 list. Status updates land here when they happen.
Want to go deeper?
Mechanism, the AMPK-activator story, and references.
Background
AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), also known as acadesine, is a small-molecule adenosine analog. Used in research as an AMPK activator since the 1990s.
Mechanism of action
AICAR is taken up by cells and phosphorylated to ZMP, an AMP analog. AMPK (AMP-activated protein kinase) is allosterically activated by AMP/ZMP, switching on a metabolic program associated with low energy state, increased glucose uptake, fatty acid oxidation, mitochondrial biogenesis, and reduced anabolic processes. This is the same metabolic program activated by exercise and caloric restriction.
References
- Hardie DG, Ross FA, Hawley SA. (2012). "AMPK: a nutrient and energy sensor that maintains energy homeostasis." Nat Rev Mol Cell Biol, 13(4), 251–262. PubMed
- Narkar VA, Downes M, Yu RT, et al. (2008). "AMPK and PPARδ agonists are exercise mimetics." Cell, 134(3), 405–415. PubMed
- Newman MF, Ferguson TB, White JA, et al. (2012). "Effect of adenosine-regulating agent acadesine on morbidity and mortality associated with coronary artery bypass grafting: the RED-CABG randomized controlled trial." JAMA, 308(2), 157–164. PubMed